The US Food and Drug Administration (FDA) has approved the first prescription therapy in nearly a decade for the treatment of superficial basal cell carcinoma (sBCC), a type of nonmelanoma skin cancer. Earlier this year, the FDA approved the same treatment for actinic keratosis (AK), which is a precancerous skin condition with lesions often occurring on the face or scalp. Both AK and sBCC are skin conditions caused by chronic sun exposure.
Go to Previous Page
Go to Next Page